REVESTIVE 5 mg Powder and solvent for solution for injection Ref.[9240] Active ingredients: Teduglutide

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Takeda Pharmaceuticals International AG Ireland Branch, Block 2 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, medinfoEMEA@takeda.com

Product name and form

Revestive 5 mg powder and solvent for solution for injection.

Pharmaceutical Form

Powder and solvent for solution for injection.

The powder is white and the solvent is clear and colourless.

Qualitative and quantitative composition

One vial of powder contains 5 mg of teduglutide*.

After reconstitution, each vial contains 5 mg teduglutide in 0.5 ml of solution, corresponding to a concentration of 10 mg/ml.

* A glucagon-like peptide-2 (GLP-2) analogue produced in Escherichia coli cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Teduglutide

Teduglutide is an analogue of GLP-2. The naturally occurring human glucagon-like peptide-2 (GLP-2) is a peptide secreted by L cells of the intestine which is known to increase intestinal and portal blood flow, inhibit gastric acid secretion, and decrease intestinal motility. In several nonclinical studies, teduglutide has been shown to preserve mucosal integrity by promoting repair and normal growth of the intestine through an increase of villus height and crypt depth.

List of Excipients

Powder:

L-histidine
Mannitol
Sodium phosphate monohydrate
Disodium phosphate heptahydrate
Sodium hydroxide (pH adjustment)
Hydrochloric acid (pH adjustment)

Solvent:

Water for injections

Pack sizes and marketing

Powder:

3 ml vial (glass) with rubber stopper (bromobutyl) containing 5 mg teduglutide.

Solvent:

Pre-filled syringe (glass) with plungers (bromobutyl) containing 0.5 ml of solvent.

Pack sizes of 1 vial of powder with 1 pre-filled syringe or 28 vials of powder with 28 pre-filled syringes.

Not all pack sizes may be marketed.

Marketing authorization holder

Takeda Pharmaceuticals International AG Ireland Branch, Block 2 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, medinfoEMEA@takeda.com

Marketing authorization dates and numbers

EU/1/12/787/001
EU/1/12/787/002

Date of first authorisation: 30 August 2012
Date of latest renewal: 23 June 2017

Drugs

Drug Countries
REVESTIVE Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Japan, Lithuania, New Zealand, Poland, Romania, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.